Nature Communications (Oct 2021)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
- Sue Ann Costa Clemens,
- Pedro M. Folegatti,
- Katherine R. W. Emary,
- Lily Yin Weckx,
- Jeremy Ratcliff,
- Sagida Bibi,
- Ana Verena De Almeida Mendes,
- Eveline Pipolo Milan,
- Ana Pittella,
- Alexandre V. Schwarzbold,
- Eduardo Sprinz,
- Parvinder K. Aley,
- David Bonsall,
- Christophe Fraser,
- Michelle Fuskova,
- Sarah C. Gilbert,
- Daniel Jenkin,
- Sarah Kelly,
- Simon Kerridge,
- Teresa Lambe,
- Natalie G. Marchevsky,
- Yama F. Mujadidi,
- Emma Plested,
- Maheshi N. Ramasamy,
- Peter Simmonds,
- Tanya Golubchik,
- Merryn Voysey,
- Andrew J. Pollard,
- the AMPHEUS Project,
- Oxford COVID Vaccine Trial Team
Affiliations
- Sue Ann Costa Clemens
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford
- Pedro M. Folegatti
- The Jenner Institute, Nuffield Department of Medicine, University of Oxford
- Katherine R. W. Emary
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford
- Lily Yin Weckx
- Department of Pediatrics, Universidade Federal de São Paulo
- Jeremy Ratcliff
- Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford
- Sagida Bibi
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford
- Ana Verena De Almeida Mendes
- Escola Bahiana de Medicina e Saúde Pública, Brazil and ID’OR
- Eveline Pipolo Milan
- Universidade Federal do Rio Grande do Norte - UFRN
- Ana Pittella
- Hospital Quinta D’Or
- Alexandre V. Schwarzbold
- Clinical Research Unit, Department of Clinical Medicine, Universidade Federal de Santa Maria
- Eduardo Sprinz
- Infectious Diseases Service, Hospital de Clinicas de Porto Alegre
- Parvinder K. Aley
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford
- David Bonsall
- Big Data Institute, Nuffield Department of Medicine, University of Oxford
- Christophe Fraser
- Big Data Institute, Nuffield Department of Medicine, University of Oxford
- Michelle Fuskova
- The Jenner Institute, Nuffield Department of Medicine, University of Oxford
- Sarah C. Gilbert
- The Jenner Institute, Nuffield Department of Medicine, University of Oxford
- Daniel Jenkin
- The Jenner Institute, Nuffield Department of Medicine, University of Oxford
- Sarah Kelly
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford
- Simon Kerridge
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford
- Teresa Lambe
- The Jenner Institute, Nuffield Department of Medicine, University of Oxford
- Natalie G. Marchevsky
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford
- Yama F. Mujadidi
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford
- Emma Plested
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford
- Maheshi N. Ramasamy
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford
- Peter Simmonds
- Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford
- Tanya Golubchik
- Oxford Viral Sequencing Group, Wellcome Centre for Human Genetics, University of Oxford
- Merryn Voysey
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford
- Andrew J. Pollard
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford
- the AMPHEUS Project
- Oxford COVID Vaccine Trial Team
- DOI
- https://doi.org/10.1038/s41467-021-25982-w
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 10
Abstract
Emerging variants of SARS-CoV-2 raise concerns about vaccine efficiency. Here, the authors present a post-hoc analysis for the ChAdOx1 nCoV-19 (AZD1222) vaccine trial in Brazil and provide efficacy against symptomatic COVID-19 caused by the Zeta (P.2) and other variants.
